Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10394883 | 0.99 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EMAPTMAPK1GAA | |
| SCHEMBL9395064 | 0.99 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EMAPTMAPK1GAA | |
| SCHEMBL6885101 | 0.99 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EMAPTMAPK1GAA | |
| SCHEMBL9116970 | 0.99 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EMAPTMAPK1GAA | |
| SCHEMBL9394689 | 0.99 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EMAPTMAPK1GAA | |
| SCHEMBL9298051 | 0.88 | ALDH1A1 (0.47) | SMN1; SMN2KDM4EMAPTMAPK1GAA | |
| SCHEMBL5093687 | 0.87 | HPGD (0.54) | SMN1; SMN2KDM4EMAPTMAPK1GAA | |
| SCHEMBL8002917 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EMAPTMAPK1GAA | |
| SCHEMBL7745866 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EMAPK1GAAL3MBTL1 | |
| SCHEMBL9392009 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPK1GAAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016004212-A1 | HYDROGELS FOR TREATING AND AMELIORATING WOUNDS AND METHODS FOR MAKING AND USING THEM | VICUS THERAPEUTICS, LLC (US) | 2016-01-07 | — | — | WO | claimed |
| EP-2490702-A1 | TREATMENT USING REPROGRAMMED MATURE ADULT CELLS | Tristem Trading (Cyprus) Limited (CY) | 2012-08-29 | — | — | EP | claimed |
| EP-2259844-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | Vicus Therapeutics SPE 1, LLC (US) | 2010-12-15 | — | — | EP | claimed |
| WO-2009111648-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS, LLC (US) | 2009-09-11 | — | — | WO | claimed |
| WO-2009097095-A2 | METHODS FOR TREATING HEMATOPOIETIC MALIGNANCIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-06 | — | — | WO | claimed |
| WO-2008033754-A2 | XANTHINE DERIVATIVES IN METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DEPRESSION | DUKE UNIVERSITY (US) | 2008-03-20 | — | — | WO | claimed |
| WO-2001032156-A2 | METHODS FOR TREATING FIBROPROLIFERATIVE DISEASES | DALHOUSIE UNIVERSITY (CA) | 2001-05-10 | — | — | WO | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| WO-1992007585-A1 | THE USE OF ANTIBODIES TO TNF OR FRAGMENTS DERIVED THEREOF AND XANTHINE DERIVATIVES FOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR | CELLTECH LIMITED (GB) | 1992-05-14 | — | — | WO | claimed |
| JP-55122779-A | — | — | None | — | — | JP | disclosed |
| WO-2023283631-A2 | METHODS FOR DIFFERENTIATING AND SCREENING STEM CELLS | THE BROAD INSTITUTE, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-3638244-A1 | PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES, AND THEIR USE | Harrow IP, LLC (US) | 2020-04-22 | — | — | EP | disclosed |
| WO-2020069005-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OR TREATMENT OF CYTOKINE RELEASE SYNDROME | HARROW HEALTH, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-3472190-A1 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY | ETH Zurich (CH) | 2019-04-24 | — | — | EP | disclosed |
| WO-1993017684-A2 | ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| WO-1992007585-A1 | THE USE OF ANTIBODIES TO TNF OR FRAGMENTS DERIVED THEREOF AND XANTHINE DERIVATIVES FOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR | CELLTECH LIMITED (GB) | 1992-05-14 | — | — | WO | disclosed |
| EP-0252487-B1 | PACKAGE CONTAINING DRUG COMBINATIONS FOR SUCCESSIVE ADMINISTRATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-08 | — | — | EP | disclosed |
| EP-0252487-A2 | Package containing drug combinations for successive administration | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-13 | — | — | EP | disclosed |
| EP-0157098-A1 | Xanthine derivatives, pharmaceuticals compositions containing them and a process for their preparation | Beecham Wuelfing GmbH & Co KG (DE) | 1985-10-09 | — | — | EP | disclosed |
| JP-S55122779-A | PREPARATION OF THEOBROMINE DERIVATIVE | MARUKO SEIYAKU KK | 1980-09-20 | — | — | JP | disclosed |